Literature DB >> 27816197

Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes.

Damien Massalou1, Emmanuel Benizri2, Anne Chevallier3, Valérie Duranton-Tanneur4, Florence Pedeutour4, Daniel Benchimol5, Jean-Marc Béréder5.   

Abstract

BACKGROUND: The objective of this study was to identify the prognostic impact of parameters in peritoneal carcinomatosis from colorectal cancer.
METHODS: We collected data from patients treated by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy for peritoneal carcinomatosis secondary to colorectal cancer.
RESULTS: Ninety-one procedures were performed. In univariate analysis, an increased peritoneal cancer index was associated with decreased survival (P < .001). The presence of signet ring cells was associated to a decrease in survival from 45.8 to 12.1 months (P < .001). Microsatellite sequences instability status was the only molecular prognostic factor correlated with an increase in median disease-free survival: 12.4 vs 24.9 months (P = .01). The presence of a mucinous component was associated with a decreased of survival from 51.9 to 35.1 months (P = .02).
CONCLUSIONS: Clinical factors were affecting the survival of patients. The absence of signet ring cells and mucinous component and the presence of microsatellite sequences instability may be favorable prognostic factors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; HIPEC; KRAS; MSI; Peritoneal carcinomatosis; Signet ring cell

Mesh:

Substances:

Year:  2016        PMID: 27816197     DOI: 10.1016/j.amjsurg.2016.03.008

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  17 in total

Review 1.  New insights in the pathology of peritoneal surface malignancy.

Authors:  Norman John Carr
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 2.  Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review.

Authors:  Christin Lund-Andersen; Annette Torgunrud; Karianne Giller Fleten; Kjersti Flatmark
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  Quality Standards for Surgery of Colorectal Peritoneal Metastasis After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Authors:  Alfonso García-Fadrique; Rafael Estevan Estevan; Luis Sabater Ortí
Journal:  Ann Surg Oncol       Date:  2021-08-25       Impact factor: 5.344

4.  Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Authors:  Marco Tonello; Dario Baratti; Paolo Sammartino; Andrea Di Giorgio; Manuela Robella; Cinzia Sassaroli; Massimo Framarini; Mario Valle; Antonio Macrì; Luigina Graziosi; Federico Coccolini; Piero Vincenzo Lippolis; Roberta Gelmini; Marcello Deraco; Daniele Biacchi; Francesco Santullo; Marco Vaira; Katia Di Lauro; Fabrizio D'Acapito; Fabio Carboni; Giuseppe Giuffrè; Annibale Donini; Paola Fugazzola; Pinuccia Faviana; Lorena Sorrentino; Antonio Scapinello; Paola Del Bianco; Antonio Sommariva
Journal:  Ann Surg Oncol       Date:  2021-11-16       Impact factor: 5.344

5.  Does the primary tumour location affect the prognosis of patients with colorectal cancer peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?

Authors:  Haipeng Chen; Sicheng Zhou; Jianjun Bi; Qiang Feng; Zheng Jiang; Jianping Xu; Wei Pei; Jianwei Liang; Zhixiang Zhou; Xishan Wang
Journal:  World J Surg Oncol       Date:  2021-08-26       Impact factor: 2.754

6.  Prognostic Impact of Primary Side and RAS/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases.

Authors:  Dario Baratti; Shigeki Kusamura; Monica Niger; Federica Perrone; Massimo Milione; Laura Cattaneo; Marcello Guaglio; Valentina Bartolini; Filippo Pietrantonio; Marcello Deraco
Journal:  Ann Surg Oncol       Date:  2020-09-24       Impact factor: 5.344

Review 7.  Colorectal Peritoneal Metastases: A Systematic Review of Current and Emerging Trends in Clinical and Translational Research.

Authors:  Foteini Stefania Koumpa; Diamantis Xylas; Maciej Konopka; Dieter Galea; Kirill Veselkov; Anthony Antoniou; Akash Mehta; Reza Mirnezami
Journal:  Gastroenterol Res Pract       Date:  2019-04-01       Impact factor: 2.260

8.  Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.

Authors:  Wilhelm Graf; Peter H Cashin; Lana Ghanipour; Malin Enblad; Johan Botling; Alexei Terman; Helgi Birgisson
Journal:  Ann Surg Oncol       Date:  2019-09-30       Impact factor: 5.344

9.  Gains of Chromosome 1p and 15q are Associated with Poor Survival After Cytoreductive Surgery and HIPEC for Treating Colorectal Peritoneal Metastases.

Authors:  Malin Enblad; Wilhelm Graf; Alexei Terman; Pascal Pucholt; Björn Viklund; Anders Isaksson; Helgi Birgisson
Journal:  Ann Surg Oncol       Date:  2019-10-16       Impact factor: 5.344

10.  Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.

Authors:  Aurélie Rondon; Sébastien Schmitt; Arnaud Briat; Nancy Ty; Lydia Maigne; Mercedes Quintana; Rosemery Membreno; Brian M Zeglis; Isabelle Navarro-Teulon; Jean-Pierre Pouget; Jean-Michel Chezal; Elisabeth Miot-Noirault; Emmanuel Moreau; Françoise Degoul
Journal:  Theranostics       Date:  2019-09-19       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.